Figure 2.
Flow-mediated vasodilation (FMD, mean + SEM) before (baseline; gold bars) and after (blue bars) 3 months of bosentan treatment in patients with idiopathic pulmonary arterial hypertension (IPAH) or PAH with other comorbidities (left) or patients who had PAH with collagen tissue disease (CTD; right).